SNUS Sonus Pharmaceuticals (MM)

Sonus Pharmaceuticals, Inc. (NASDAQ: SNUS) today announced that Michael A. Martino, President and Chief Executive Officer, will present at the Lazard Capital Markets Third Annual Life Sciences Conference at 2:00 P.M. Eastern Time on Wednesday, November 29, in New York City. The Company�s presentation will be broadcast live and archived on the Sonus web site at www.sonuspharma.com/events.html. Sonus� lead oncology product candidate is TOCOSOL� Paclitaxel, a new formulation of the widely prescribed anti-cancer drug, paclitaxel. TOCOSOL Paclitaxel is currently in a Phase 3 pivotal trial for the potential treatment of metastatic breast cancer. The trial is being conducted under a Special Protocol Assessment with the U.S. Food and Drug Administration. Patient enrollment in the Phase 3 trial was completed in November 2006. The New Drug Application submission for TOCOSOL Paclitaxel is targeted for the end of 2007. About Sonus Pharmaceuticals, Inc. Headquartered near Seattle, Sonus Pharmaceuticals is focused on the development of cancer drugs that are designed to provide improved efficacy, safety and tolerability, and are more convenient to use. In addition to the continuing advancement of TOCOSOL Paclitaxel, Sonus initiated the Phase 1 clinical development program for its second product candidate, TOCOSOL Camptothecin, in September 2006. TOCOSOL Camptothecin is a new entry in the same drug class as the approved camptothecin analogs, irinotecan and topotecan. Preclinical data suggest that TOCOSOL Camptothecin may be more efficacious and better tolerated than irinotecan. For additional information on Sonus, including news releases, please visit www.sonuspharma.com. Safe Harbor Certain statements made in this press release are forward-looking such as those, among others, relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products. As discussed in Sonus Pharmaceuticals� filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for 2005 and Quarterly Report on Form 10-Q for the third quarter of 2006, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: the Company�s products will require extensive clinical testing and approval by regulatory authorities; such approvals are lengthy and expensive and may never occur; risks that the Company will not be able to complete the Phase 3 clinical trial for TOCOSOL Paclitaxel; risks that clinical studies with TOCOSOL Paclitaxel will be delayed or will not be successful; risks that the FDA may not approve the TOCOSOL Paclitaxel New Drug Application; risks that the Phase 1 clinical trial for TOCOSOL Camptothecin will not be successful; risks of successful development of therapeutic drugs; and risks that the Company may not be successful in obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies as well as research and development activities. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof. Sonus Pharmaceuticals, Inc. (NASDAQ: SNUS) today announced that Michael A. Martino, President and Chief Executive Officer, will present at the Lazard Capital Markets Third Annual Life Sciences Conference at 2:00 P.M. Eastern Time on Wednesday, November 29, in New York City. The Company's presentation will be broadcast live and archived on the Sonus web site at www.sonuspharma.com/events.html. Sonus' lead oncology product candidate is TOCOSOL(R) Paclitaxel, a new formulation of the widely prescribed anti-cancer drug, paclitaxel. TOCOSOL Paclitaxel is currently in a Phase 3 pivotal trial for the potential treatment of metastatic breast cancer. The trial is being conducted under a Special Protocol Assessment with the U.S. Food and Drug Administration. Patient enrollment in the Phase 3 trial was completed in November 2006. The New Drug Application submission for TOCOSOL Paclitaxel is targeted for the end of 2007. About Sonus Pharmaceuticals, Inc. Headquartered near Seattle, Sonus Pharmaceuticals is focused on the development of cancer drugs that are designed to provide improved efficacy, safety and tolerability, and are more convenient to use. In addition to the continuing advancement of TOCOSOL Paclitaxel, Sonus initiated the Phase 1 clinical development program for its second product candidate, TOCOSOL Camptothecin, in September 2006. TOCOSOL Camptothecin is a new entry in the same drug class as the approved camptothecin analogs, irinotecan and topotecan. Preclinical data suggest that TOCOSOL Camptothecin may be more efficacious and better tolerated than irinotecan. For additional information on Sonus, including news releases, please visit www.sonuspharma.com. Safe Harbor Certain statements made in this press release are forward-looking such as those, among others, relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products. As discussed in Sonus Pharmaceuticals' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for 2005 and Quarterly Report on Form 10-Q for the third quarter of 2006, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: the Company's products will require extensive clinical testing and approval by regulatory authorities; such approvals are lengthy and expensive and may never occur; risks that the Company will not be able to complete the Phase 3 clinical trial for TOCOSOL Paclitaxel; risks that clinical studies with TOCOSOL Paclitaxel will be delayed or will not be successful; risks that the FDA may not approve the TOCOSOL Paclitaxel New Drug Application; risks that the Phase 1 clinical trial for TOCOSOL Camptothecin will not be successful; risks of successful development of therapeutic drugs; and risks that the Company may not be successful in obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies as well as research and development activities. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.